Profica's collaboration with CBRE Design Collective shows a powerful integration of local expertise and global standards.

UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...

In a report released today, Matthew Weston from UBS upgraded AstraZeneca (AZN – Research Report) to a Buy, with a price target of £142.00. The ...

Investors with a lot of money to spend have taken a bullish stance on AstraZeneca AZN. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Jordan Brand's "Vivid Purple" Jordan 3 has a Joker-esque colour palette that is sure to have you grinning from ear to ear.

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18,745.88 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is ...